Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Heron Therapeutics (NASDAQ:HRTX) and maintained a $5 price target.
August 07, 2024 | 10:21 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Heron Therapeutics and maintained a $5 price target.
The reiteration of a Buy rating and maintenance of a $5 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100